Sibutramine

This page shows anti-doping rule violation data we have registered for Sibutramine.

Number of cases in Sibutramine Last 10 Years

Sibutramine

Sibutramine ranks #53 globally among prohibited substances, with 67 registered cases (0.5% of all violations) among all sports tracked by the Anti-Doping Database, which contains 14,670 verified cases. Brazil leads with 10 cases, while Track and field is the most affected sport (8 cases).

Cases of Sibutramine by Sport
Track and field
8
Soccer
7
Weightlifting
7
Cycling
6
Handball
5
Top Sport: Track and field

8

Track and field cases

0%

Of all violations

67

Total Sibutramine cases
Track and field's share of Sibutramine violations 0%
8 of 67

Track and field has the most recorded cases of Sibutramine violations globally, with 8 registered cases — 0% of all 67 verified cases.

Cases of Sibutramine by Country
Brazil
10
South Africa
8
Russia
5
Malaysia
3
France
3
Top Country: Brazil

10

Brazil cases

14.9%

Of all violations

67

Total Sibutramine cases
Brazil's share of Sibutramine violations 14.9%
10 of 67

Brazil leads in Sibutramine violations globally, with 10 registered cases — 14.9% of all 67 verified cases.

Global Substance Ranking

Sibutramine ranks #53 of 358 prohibited substances in the Anti-Doping Database.

#1 Stanozolol
1,359
#2 Methandienone
833
#3 Norandrosterone
778
#4 Testosterone
758
···
#53 Sibutramine
66
About This Ranking

This ranking covers only prohibited substances with verified case records in the Anti-Doping Database. Procedural violations (whereabouts failures, refusals to test, etc.) are excluded.

Active Sanctions — Expiry Year
Gender Distribution
Male 62.7%
42 cases
Female 37.3%
25 cases
Analysis: shows an unusually high proportion of female cases (37.3%) compared to the global average (19.8%), a difference of 17.5 percentage points. Global average: 80.2% male, 19.8% female
Average Suspension Length
21.7
months
Sibutramine
30.1
months
Global average

The average suspension for Sibutramine violations is 21.7 months, shorter than the global average of 30.1 months.

Sibutramine is used in combination with a reduced calorie diet and exercise to help people who are overweight lose weight and maintain their weight loss. Sibutramine is in a class of medications called appetite suppressants. It works by acting on appetite control centers in the brain to decrease appetite. Sibutramine is also know under its brand name Merida. NOTE: Sibutramine is no longer available in the U.S. It was withdrawn from the U.S. market in October 2010. The manufacturer has decided to stop producing sibutramine based on information from a recent clinical study. In this study, people taking sibutramine had an increased risk of cardiovascular events such as heart attack and stroke. If you are currently taking sibutramine, you should stop taking this medication and call your doctor to discuss switching to another treatment for weight loss or maintenance of weight loss. Sources: drugs.com: http://www.drugs.com/mtm/sibutramine.html WADA: http://list.wada-ama.org/list/s6-stimulants/sibutramine/ Medline Plus: http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601110.html

If you use this data, please credit The Anti-Doping Database

The intelligence tool for anti-doping professionals

Used by journalists, sport lawyers, NADOs and researchers worldwide for proactive strategy — not just post-case research.

 

As a subscriber you get instant access to verified, structured anti-doping case data — from hours of research to seconds:

  • Complete athlete and sanction details
    • Identity, ban periods, substances used, test type, violation information and more.
  • Verified documents and case materials
    • Access sanction decisions, PDFs and official sources when available.
  • Advanced insights and historical trends
    • Statistics across sports, countries, substances and year-by-year comparisons — for proactive planning, not just post-case analysis.

The Anti-Doping Database currently contains 14,670 verified anti-doping rule violations across all sports and all countries, and is updated regularly.